Quoin Pharmaceuticals (QNRX) Registration Filing summary

Company overview and business model

• Clinical-stage specialty pharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases with no approved treatments, initially targeting rare skin diseases.

• Lead product QRX003, a topical lotion for Netherton Syndrome, is in late-stage clinical development, with additional candidates for other rare dermatological and systemic conditions.

• Pipeline includes QRX003, QRX004, QRX007, and QRX008, with ongoing and planned clinical studies in the US, Europe, Middle East, and Asia-Pacific.

• Business strategy includes completing late-stage clinical trials, seeking regulatory approvals, building sales infrastructure in the US and Europe, and establishing global distribution partnerships.

Financial performance and metrics

• As of September 30, 2024, cash and short-term investments were $10.3 million; pro forma post-offering cash would be $23.7 million if the maximum is raised.

• Accumulated deficit stands at $52.9 million, with shareholders' equity of $5.4 million actual and $18.8 million as adjusted for the offering.

• Historical net tangible book value per ADS was $0.98; post-offering, as adjusted, would be $0.75 per ADS, resulting in immediate dilution of $0.03 per ADS to new investors.

Use of proceeds and capital allocation

• Estimated net proceeds of $13.4 million if the maximum is raised, with no minimum offering amount required.

• Proceeds intended for general corporate purposes, including operating expenses, R&D, clinical and pre-clinical testing, working capital, future acquisitions, and capital expenditures.

• Management retains broad discretion over allocation; proceeds may be invested in short-term, investment-grade instruments pending use.